Urology Medical News about Urinary Bladder, Overactive Fesoterodine

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Fesoterodine: a new antimuscarinic for overactive bladder
Aging Health, 10/13/09

Guay DRP – Fesoterodine therapy (4 and 8 mg once daily) significantly reduced the numbers of micturitions and urge incontinence episodes per 24 h and increased the volume voided per micturition as compared with placebo in three published randomized, controlled trials. It has been compared with tolterodine long–acting in one of these randomized, controlled trials, but the results of fesoterodine and tolterodine long–acting were not compared statistically. Fesoterodine produces the same well–known adverse events as other urinary anticholinergics. The initial recommended dosage regimen is 4 mg once daily, which can be titrated up to 8 mg once daily based upon response. However, the following patient populations should not receive over 4 mg daily: patients with severe renal impairment (creatinine clearance <30 ml/min) and those receiving concurrent therapy with potent CYP450 isozyme 3A4 inhibitors (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, ritonavir and nelfinavir).

<< Previous
Risk of dying from prostate cancer in men randomized to screening

Next >>
Testicular function after treatment for acute lymphoblastic...